Physician profile
John M Morton
NPI 1972638054
$970,304.27
in general payments reported to CMS, 2019-2025
25 companies · $124K in 2025
The $124K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226K · 2020: $121K · 2021: $129K · 2022: $99K · 2023: $122K · 2024: $148K · 2025: $124K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $254K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Travel and Lodging: $57K · Acquisitions: $13K · Food and Beverage: $4,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $254,354.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,262.50 |
| Travel and Lodging | $56,882.25 |
| Acquisitions | $13,323.68 |
| Food and Beverage | $4,870.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $385,034.82 | 2019-2025 | Wegovy |
| Novo Nordisk As | $139,638.29 | 2019-2025 | |
| Medical Device Business Services, INC. | $114,041.13 | 2019-2024 | Echelon Flex, Harmonic, Echelon; Endopath |
| Teleflex LLC | $92,440.06 | 2023-2025 | Titan Sgs, Titan Sgs Bailout Chuck, Titan Sgs Standard Gastric Stapler |
| Olympus America INC. | $74,032.37 | 2019-2025 | Gastrointestinal Videoscope, 4k Cable 3.0m, Evis Exera III Colonovideoscope |
| Olympus Corporation of The Americas | $34,455.85 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31,393.36 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $18,020.47 | 2024-2025 | |
| Olympus Latin America, INC. | $16,598.01 | 2019-2020 | |
| Olympus Corporation | $11,727.79 | 2020-2023 | |
| Johnson & Johnson Medical Devices & Diagnostics Group - Latin America, L.L.C. | $11,013.00 | 2019 | |
| Lilly USA, LLC | $10,088.48 | 2023 | Mounjaro |
| Standard Bariatrics, INC. | $8,009.84 | 2021-2023 | Titan Sgs Standard Gastric Stapler |
| Covidien Lp | $6,507.03 | 2019-2020 | |
| Gyrus Acmi, INC. | $4,550.00 | 2024 | High Flow Insufflation Unit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $4,000.00 | 2022 | |
| Glaxosmithkline, LLC. | $4,000.00 | 2019 | |
| Heron Therapeutics, INC. | $2,312.98 | 2022 | |
| Teleflex Incorporated | $1,790.90 | 2023 | Deknatel |
| W. L. Gore & Associates, INC. | $219.45 | 2019 | |
| Medtronic, INC. | $176.81 | 2023-2025 | Signia |
| Baxter Healthcare | $122.70 | 2019 | |
| Ethicon US, LLC | $49.58 | 2019 | |
| Intuitive Surgical, INC. | $43.75 | 2025 | |
| Apollo Endosurgery US INC | $37.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$60,272.30 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.